{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:58:21Z","timestamp":1781272701148,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dry eye disease (DED) is a common ocular surface disorder with limitations in conventional therapies. Perfluorohexyloctane ophthalmic solution, a novel formulation, has demonstrated short-term efficacy, but real-world safety data are insufficient. This study aimed to conduct a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database to provide evidence-based references for clinical rational drug use, risk management, and long-term DED treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective pharmacovigilance study using FAERS data from the fourth quarter of 2023 through the fourth quarter of 2024, focusing on adverse events (AEs) associated with perfluorohexyloctane ophthalmic solution for DED. Four disproportionality analysis methods, the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS), were employed to identify potential safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 92 AEs reports associated with perfluorohexyloctane ophthalmic solution for DED were identified. At the Preferred Term (PT) level, the top five reports by count included product delivery mechanism issue, eye irritation, inappropriate schedule of product administration, vision blurred, and ocular hyperaemia. The top five AEs meeting positive signal criteria were wrong dose, exposure via skin contact, patient dissatisfaction with treatment, product dose omission in error, and circumstance or information capable of leading to medication error. The median time-to-onset for perfluorohexyloctane-related AEs was 2\u202fdays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, the available FAERS data do not raise major safety concerns for perfluorohexyloctane ophthalmic solution in the treatment of DED. The reported AEs appear to be mostly related to the instillation process, user experience with the delivery device, or the initial adaptation period, rather than directly attributable to the drug itself. Larger post-marketing studies are warranted to further characterize the safety profile of perfluorohexyloctane ophthalmic solution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1832619","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:54:12Z","timestamp":1779944052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhengtai","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Que","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"Tfos dews ii definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1531670","DOI":"10.3389\/fmed.2024.1531670","article-title":"Therapeutic benefits of glycerol in dry eye disease","volume":"11","author":"Ronderos","year":"2024","journal-title":"Front Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"19787","DOI":"10.12677\/acm.2023.13122785","article-title":"Clinical research progress of dry eye","volume":"13","author":"Wang","year":"2023","journal-title":"Prog. Clin. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/jop.2019.0092","article-title":"Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial","volume":"36","author":"Schmidl","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1089\/jop.2017.0042","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease due to Meibomian gland disease","volume":"33","author":"Steven","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/jop.2015.0048","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease--a prospective, multicenter noninterventional study","volume":"31","author":"Steven","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1097\/ico.0000000000003418","article-title":"Long-term safety and efficacy of Perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the Kalahari study","volume":"43","author":"Protzko","year":"2024","journal-title":"Cornea"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"20420986241285929","DOI":"10.1177\/20420986241285929","article-title":"Adverse events of topical ocular prostaglandin medications for Glaucoma treatment: a pharmacovigilance study based on the Faers database","volume":"15","author":"Wu","year":"2024","journal-title":"Ther Adv Drug Safety"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1655216","DOI":"10.3389\/fneur.2025.1655216","article-title":"Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the Fda adverse event reporting system","volume":"16","author":"Li","year":"2025","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"13407","DOI":"10.1038\/s41598-025-92796-x","article-title":"Real-world pharmacovigilance analysis of drug-related conjunctivitis using the Fda adverse event reporting system database","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1420478","DOI":"10.3389\/fphar.2024.1420478","article-title":"Safety of Tildrakizumab: a disproportionality analysis based on the Fda adverse event reporting system (Faers) database from 2018-2023","volume":"15","author":"Lin","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1389814","DOI":"10.3389\/fphar.2024.1389814","article-title":"Post-marketing safety concerns with Lumateperone: a pharmacovigilance analysis based on the Fda adverse event reporting system (Faers) database","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40360-025-00867-6","article-title":"Risk of drug-induced pericardial effusion: a disproportionality analysis of the Faers database","volume":"26","author":"Ren","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"Nov03 for dry eye disease associated with Meibomian gland dysfunction: results of the randomized phase 3 Gobi study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"Nov03 for signs and symptoms of dry eye disease associated with Meibomian gland dysfunction: the randomized phase 3 Mojave study","volume":"252","author":"Sheppard","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamaophthalmol.2023.0270","article-title":"Perfluorohexyloctane eye drops for dry eye disease associated with Meibomian gland dysfunction in Chinese patients: a randomized clinical trial","volume":"141","author":"Tian","year":"2023","journal-title":"JAMA Ophthal"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1452422","DOI":"10.3389\/fopht.2024.1452422","article-title":"Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials","volume":"4","author":"Fahmy","year":"2024","journal-title":"Front Ophthal"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000542149","article-title":"Efficacy of Perfluorohexyloctane for the treatment of patients with dry eye disease: a Meta-analysis","volume":"68","author":"Taloni","year":"2025","journal-title":"Ophthalmic Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e67920","DOI":"10.7759\/cureus.67920","article-title":"Efficacy and safety of Perfluorohexyloctane in evaporative dry eye disease associated with Meibomian gland dysfunction: a systematic review and Meta-analysis of randomized controlled trials","volume":"16","author":"Guedes","year":"2024","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3238\/arztebl.2015.0071","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Deutsches Arzteblatt Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020207","article-title":"Formulation considerations for the Management of dry eye Disease","volume":"207","author":"Agarwal","year":"2021","journal-title":"Pharmaceutics"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.37765\/ajmc.2023.89464","article-title":"A review of the first anti-evaporative prescription treatment for dry eye disease: Perfluorohexyloctane ophthalmic solution","volume":"29","author":"Sheppard","year":"2023","journal-title":"Am J Manag Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-026-04007-9","article-title":"Perfluorohexyloctane eye drops in treating dry eye disease associated with Meibomian gland dysfunction: a post hoc analysis by baseline severity","volume":"171","author":"Liu","year":"2026","journal-title":"Int Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1756286420985237","DOI":"10.1177\/1756286420985237","article-title":"Cerebrovascular disease in women","volume":"14","author":"Kumar","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.18632\/aging.101931","article-title":"Aging and ischemic stroke","volume":"11","author":"Yousufuddin","year":"2019","journal-title":"Aging"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40123-025-01097-z","article-title":"Early effects of perfluorohexyloctane ophthalmic solution on patient-reported outcomes in dry eye disease: a prospective, open-label, multicenter study","volume":"14","author":"Bacharach","year":"2025","journal-title":"Ophthalmol Therapy"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0328235","DOI":"10.1371\/journal.pone.0328235","article-title":"Incidence of dry eye symptoms and Behavioural-cultural risk factors among university students population in Jordan","volume":"20","author":"Bakkar","year":"2025","journal-title":"PLoS One"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832619\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:20:00Z","timestamp":1781270400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832619\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":27,"alternative-id":["10.3389\/fmed.2026.1832619"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1832619","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1832619"}}